logo-loader
viewVolitionRx

Growth 'guaranteed' for a well funded Volition Rx

Cameron Reynolds, CEO of Volition Rx, the NYSE-listed company, brings Proactive Investors London an end of quarter catch up with newsflows in three key areas. First there's more news on their new routine blood test to screen for colorectal and prostate cancers which has reduced the need for more invasive colonoscopies and biopsies. Secondly, there's an update on the potential for further revenue streams for Volition once discovery grade assets convert to product grade opportunities. And lastly, how Volition continues to push into veterinary medicine while both well funded and keeping costs down.

Quick facts: VolitionRx

Price: 5.37 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $220.65 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx records first revenues from research kits and strengthens balance...

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds talks Proactive London's Andrew Scott through the firm's third quarter update. He says excellent progress has been made on platform development - Nu.Q Capture, Nu.Q Vet and its colorectal cancer and lung cancer trials. Volition also...

1 day, 9 hours ago

2 min read